XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1

Collaborative Agreements (Details)		1 Months Ended								3 Months Ended	12 Months Ended
	Aug. 15, 2017 USD ($)	Dec. 24, 2018	Sep. 30, 2018 USD ($)	Sep. 25, 2017 USD ($)	May 26, 2017 USD ($)	Aug. 31, 2016 USD ($)	Aug. 31, 2016 TWD ($)	Jul. 27, 2016 USD ($)	Dec. 31, 2015 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2017 USD ($)	Feb. 23, 2023 shares	Jun. 10, 2022 USD ($)	Aug. 05, 2019 USD ($) shares	Jun. 30, 2019 USD ($) shares
Collaborative Agreements (Details) [Line Items]
Milestone payments royalty percentage										12.00%
Amount received													$ 3
Co-Dev agreement, description		the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.64 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.
Shares issued (in Shares) | shares												5,291,667
BHK Co-Development Agreement [Member]
Collaborative Agreements (Details) [Line Items]
Milestone payment							$ 31,649,000	$ 10,000,000
Description of payment settlement								●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment     ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment     ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment     ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment
Upfront cash payment									$ 1,000,000
Percentage of payments under co-development agreement									10.00%
Total cash amount						$ 1,000,000			$ 10,000,000
Collaborative agreements, description									In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.64 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.	In addition to the total of NT$50 million, approximately equivalent to $1.64 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.
Co-Dev Agreement [Member]
Collaborative Agreements (Details) [Line Items]
Percentage of payments under co-development agreement					50.00%
Cash amount	$ 3,000,000
Addition cash payment					$ 3,000,000
Additional paid-in capital											$ 3,000,000
Amount received											450,000
Collaborative Agreement [Member]
Collaborative Agreements (Details) [Line Items]
Percentage of payments under co-development agreement										50.00%
Total cash amount			$ 3,000,000
Cash amount										$ 3,000,000
Licensing rights				$ 3,000,000
Research and development expense											$ 3,000,000
BioFirst Stock Purchase Agreement [Member]
Collaborative Agreements (Details) [Line Items]
Amount received														$ 2,902,911	$ 3,000,000
Shares issued (in Shares) | shares														414,702	428,571

X

- Definition

The amount of addition cash payment.

+ References

No definition available.

+ Details

Name:	abvc_AdditionCashPayment
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount received.

+ References

No definition available.

+ Details

Name:	abvc_AmountReceived
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Co-Dev agreement description.

+ References

No definition available.

+ Details

Name:	abvc_CoDevAgreementDescription
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Agreements, description

+ References

No definition available.

+ Details

Name:	abvc_CollaborativeAgreementsDescription
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvc_CollaborativeAgreementsDetailsLineItems
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The value of Common stock newly issued. for example : newly issued shares means any common shares issued pursuant to the primary share purchases.

+ References

No definition available.

+ Details

Name:	abvc_IssuanceOfStockValue
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	abvc_MilestonePayments
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Milestone payments royalty percentage.

+ References

No definition available.

+ Details

Name:	abvc_MilestonePaymentsRoyaltyPercentage
Namespace Prefix:	abvc_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of payments under co-development agreement.

+ References

No definition available.

+ Details

Name:	abvc_PercentageOfPaymentsUnderCodevelopmentAgreement
Namespace Prefix:	abvc_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of upfront payments which are paid during the term of agreement.

+ References

No definition available.

+ Details

Name:	abvc_UpfrontCashPayment
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AdditionalPaidInCapitalCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Cash payments related to participation costs.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 926
-SubTopic 230
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483170/926-230-45-1

+ Details

Name:	us-gaap_PaymentsForParticipationLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Description of the terms and manner of settlement of the related party transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: